17-beta-hydroxysteroid dehydrogenase deficiency historical perspective: Difference between revisions
No edit summary |
Jose Loyola (talk | contribs) No edit summary |
||
| (14 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{17-beta-hydroxysteroid dehydrogenase deficiency}} | {{17-beta-hydroxysteroid dehydrogenase deficiency}} | ||
{{CMG}}; {{AE}} {{Abdulkerim}} | |||
==Overview== | |||
17 beta hydroxysteroid dehydrogenase III deficiency was initially described in 1971 by [[Saez]] and his colleagues. | |||
==Historical Perspective== | |||
*17 beta hydroxysteroid dehydrogenase III deficiency was initially described in 1971 by [[Saez]] and his colleagues. | |||
*17βHSD-3 enzyme deficiency, previously termed [[17-ketosteroid reductase deficiency]], is the most common [[testosterone]] [[biosynthesis]] defect of 46,XY disorder of sex development. | |||
*It shows [[autosomal]] [[recessive]] [[inheritance]].<ref name="pmid17509588">{{cite journal| author=Mains LM, Vakili B, Lacassie Y, Andersson S, Lindqvist A, Rock JA| title=17beta-hydroxysteroid dehydrogenase 3 deficiency in a male pseudohermaphrodite. | journal=Fertil Steril | year= 2008 | volume= 89 | issue= 1 | pages= 228.e13-7 | pmid=17509588 | doi=10.1016/j.fertnstert.2007.02.048 | pmc=2259022 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17509588 }} </ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:needs english review]] | |||
Latest revision as of 07:43, 20 October 2022
|
17-beta-hydroxysteroid dehydrogenase deficiency Microchapters |
|
Differentiating 17-beta-hydroxysteroid dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
17-beta-hydroxysteroid dehydrogenase deficiency historical perspective On the Web |
|
American Roentgen Ray Society Images of 17-beta-hydroxysteroid dehydrogenase deficiency historical perspective |
|
FDA on 17-beta-hydroxysteroid dehydrogenase deficiency historical perspective |
|
CDC on 17-beta-hydroxysteroid dehydrogenase deficiency historical perspective |
|
17-beta-hydroxysteroid dehydrogenase deficiency historical perspective in the news |
|
Blogs on 17-beta-hydroxysteroid dehydrogenase deficiency historical perspective |
|
Directions to Hospitals Treating 17-beta-hydroxysteroid dehydrogenase deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdulkerim Yassin, M.B.B.S[2]
Overview
17 beta hydroxysteroid dehydrogenase III deficiency was initially described in 1971 by Saez and his colleagues.
Historical Perspective
- 17 beta hydroxysteroid dehydrogenase III deficiency was initially described in 1971 by Saez and his colleagues.
- 17βHSD-3 enzyme deficiency, previously termed 17-ketosteroid reductase deficiency, is the most common testosterone biosynthesis defect of 46,XY disorder of sex development.
- It shows autosomal recessive inheritance.[1]
References
- ↑ Mains LM, Vakili B, Lacassie Y, Andersson S, Lindqvist A, Rock JA (2008). "17beta-hydroxysteroid dehydrogenase 3 deficiency in a male pseudohermaphrodite". Fertil Steril. 89 (1): 228.e13–7. doi:10.1016/j.fertnstert.2007.02.048. PMC 2259022. PMID 17509588.